According to the report "Liquid Biopsy Market", published by Market Data Forecast, the global market is projected to reach USD 1.75 Billion by 2021, at a CAGR of 24.3% from 2016 to 2021.

For full report refer to http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/

Liquid biopsies have been an advancement in cancer treatment. By means of a simple blood draw, liquid biopsies aim to replace needle biopsies of solid tumours, which can be expensive for the healthcare system as well as invasive and painful for patients. Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue

Free sample for the report is available at http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/request-sample

Liquid biopsies have grown in importance because, the genetic profile of tumours can affect how well they respond to a certain treatment. Increasing prevalence of various cancers such as lung cancer, breast cancer and prostate cancer is expected to drive growth of the liquid biopsy test market over the forecast period.

Request customization at http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/customize-report

Global market for Liquid Biopsy is segmented on the basis of By Cancer Type , Sample Type , By Diagnostic Approach and End Users

By Cancer Type:
• Lung Cancer
• Pancreatic Cancer
• Leukemia
• Other Visceral Cancers

By Sample Type:
• Blood
• Urine
• Plasma
• Saliva
• Cerebrospinal

By Diagnostic Approach:
• Circulating Tumour cells (CTC)
• Circulating Tumour DNA (ctDNA)
• RNA in exosomes
• Extra-Cellular Vesicles

By End Users:
• Reference Laboratories
• Hospital/Physician Laboratories
• Academic and Research Centers
• Other End Users

By Geography:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle-East and Africa

Enquire more about the report at http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/inquire

The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

Buy now https://www.marketdataforecast.com/cart/buy-now/global-liquid-biopsy-market-950

About Market Data Forecast:
Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.